Home > Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia
Haematological Malignancies, Leukaemia

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Published Online: April 29th 2015

Prof Topp talks to ecancertv at ASCO 2014 about the results of a multicenter phase 2 study of the BiTE antibody blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. The use of blinatumomab is an antibody treatment which enables chemotherapy to be bypassed in some patients.

Share this Video
Related Videos In Leukaemia
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar